Navigation Links
Dr. Brad Vince, with Vince and Associates Clinical Research, Presents at the Exploratory Development World Congress 2009
Date:11/2/2009

OVERLAND PARK, Kan., Nov. 2 /PRNewswire/ -- Vince and Associates Clinical Research (VACR), a leading provider of Phase I-IV clinical research trials, announced that Dr. Bradley Vince, Medical Director and President, shared his expertise at the Exploratory Development World Congress on October 20, 2009 in Boston, Massachusetts. The Exploratory Development World Americas Congress focuses on early development strategy, including a wide range of disciplines within clinical trials including Clinical Research, Clinical Pharmacology, Phase I Trials, Exploratory Development, Regulatory Affairs, PK/PD and Clinical Operations.

The pre-conference workshop facilitated by Lorraine M. Rusch, PhD, Vice President of Business Development at VACR, was entitled Mitigating Risk in Early Clinical Development. During the session, Dr. Vince discussed Recruiting Strategies and Medical Oversight of Special Population Volunteers in Early Stage Trials. Dr. Vince related his physician perspective on the recruitment and medical management of intent-to-treat populations during early clinical research trials which enable earlier Proof of Concept (POC) drug development data to be successfully obtained.

"As a multi-specialty research unit, Vince and Associates Clinical Research is a leading provider of Phase I-IV clinical research for the pharmaceutical and biotechnology industry," said Dr. Vince. "We welcomed the opportunity to share our perspective, medical expertise and strength in early-stage drug development data at the Exploratory Development World Congress."

As the Medical Director of the Vince and Associates Clinical Research, Dr. Vince provides overall management of Phase I-IV clinical pharmacology services, including study design, feasibility, recruiting and monitoring of both healthy normal subjects and special population patients participating in clinical trials at the Overland Park, Kansas facilities.

Vince and Associates Clinical Research is a dedicated research facility that conducts Phase I-IV clinical trials for the global pharmaceutical and biotech industry. Dr. Vince has personally assembled an experienced team that focuses on quality research data and exceptional customer service while maintaining the highest ethical and professional standards. Vince and Associates has become one of the premier U.S. clinical research sites specializing in multispecialty trials. With over 275 clinical trials completed and having worked with over 70 sponsors and CROs, Vince and Associates is well known and respected for its rapid study start-up and quality study data.

Additional background materials pertaining to Vince and Associates Clinical Research is located on the corporate website at www.vinceandassociates.com.

    Bruce Copeland
    913-696-1601
    bcopeland@vinceandassociates.com

SOURCE Vince and Associates Clinical Research


'/>"/>
SOURCE Vince and Associates Clinical Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Vincent W. Renz Joins NewCardio as President
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
4. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
5. Physiotherapy Associates Marks National Physical Therapy Month With Free Educational Brochure
6. Aprimas EHR Helps Bend Urology Associates Improve Efficiency, Workflow
7. Press Ganey Partners With Health Management Associates
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/18/2017)... SAN DIEGO and BLOOMINGTON, ... Pharmaceuticals, Inc. (NASDAQ: IMMY ) ("Imprimis"), ... d/b/a Precision Lens ("Precision Lens"), today announced the ... Under the agreement, Precision Lens will deploy a ... into select geographies in the U.S., primarily focused ...
Breaking Medicine Technology:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... York, NY (PRWEB) , ... April 28, 2017 ... ... Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery and ... revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, with ... revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional back ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
Breaking Medicine News(10 mins):